Veracyte (VCYT)
(Delayed Data from NSDQ)
$20.88 USD
+0.23 (1.11%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $20.90 +0.02 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
VCYT 20.88 +0.23(1.11%)
Will VCYT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for VCYT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VCYT
Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?
Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.07%: Read This Before Placing a Bet
VCYT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Veracyte (VCYT) Crossed Above the 50-Day Moving Average: What That Means for Investors
Zacks.com featured highlights include Veracyte, Signet Jewelers, UMB Financial and NVIDIA
Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners
Other News for VCYT
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
Veracyte says new findings suggest potential of novel molecular signatures
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
July 19th Options Now Available For Veracyte (VCYT)